{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:38:32Z","timestamp":1770824312040,"version":"3.50.1"},"reference-count":22,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.1248\/bpb.b20-00903","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T22:07:44Z","timestamp":1614550064000},"page":"431-436","source":"Crossref","is-referenced-by-count":10,"title":["Deletion of TRPC3 or TRPC6 Fails to Attenuate the Formation of Inflammation and Fibrosis in Non-alcoholic Steatohepatitis"],"prefix":"10.1248","volume":"44","author":[{"given":"Kazuhiro","family":"Nishiyama","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiemi","family":"Toyama","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Kato","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"National Institute for Physiological Sciences (NIPS), National Institutes of Natural Sciences (NINS)"},{"name":"Exploratory Research Center on Life and Living Systems (ExCELLS), NINS"},{"name":"Center for Novel Science Initiatives (CNSI), National Institutes of Natural Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyuki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Kyushu University"},{"name":"National Institute for Physiological Sciences (NIPS), National Institutes of Natural Sciences (NINS)"},{"name":"Exploratory Research Center on Life and Living Systems (ExCELLS), NINS"},{"name":"Department of Physiological Sciences, SOKENDAI (School of Life Science, The Graduate University for Advanced Studies)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Nagata","sequence":"additional","affiliation":[{"name":"Medical Pharmacy, Graduate School of Pharmaceutical Sciences, Osaka University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Nishida","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Kyushu University"},{"name":"National Institute for Physiological Sciences (NIPS), National Institutes of Natural Sciences (NINS)"},{"name":"Exploratory Research Center on Life and Living Systems (ExCELLS), NINS"},{"name":"Center for Novel Science Initiatives (CNSI), National Institutes of Natural Sciences"},{"name":"Department of Physiological Sciences, SOKENDAI (School of Life Science, The Graduate University for Advanced Studies)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) de Alwis NMW, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. <i>J. Hepatol.<\/i>, <b>48<\/b>(Suppl. 1), S104\u2013S112 (2008)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sun B, Karin M. Obesity, inflammation, and liver cancer. <i>J. Hepatol.<\/i>, <b>56<\/b>, 704\u2013713 (2012).","DOI":"10.1016\/j.jhep.2011.09.020"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. <i>Semin. Liver Dis.<\/i>, <b>33<\/b>, 380\u2013388 (2013).","DOI":"10.1055\/s-0033-1358519"},{"key":"4","unstructured":"4) Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. <i>Sci. Rep.<\/i>, <b>6<\/b>, 33386\u201333386 (2016)."},{"key":"5","unstructured":"5) Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: a clinical perspective. <i>Br. J. Pharmacol.<\/i>, <b>171<\/b>, 2474\u20132507 (2014)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Numaga-Tomita T, Oda S, Nishiyama K, Tanaka T, Nishimura A, Nishida M. TRPC channels in exercise-mimetic therapy. <i>Pflugers Arch.<\/i>, <b>471<\/b>, 507\u2013517 (2019).","DOI":"10.1007\/s00424-018-2211-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kitajima N, Numaga-Tomita T, Watanabe M, Kuroda T, Nishimura A, Miyano K, Yasuda S, Kuwahara K, Sato Y, Ide T, Birnbaumer L, Sumimoto H, Mori Y, Nishida M. TRPC3 positively regulates reactive oxygen species driving maladaptive cardiac remodeling. <i>Sci. Rep.<\/i>, <b>6<\/b>, 37001 (2016).","DOI":"10.1038\/srep37001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Fu J, Du H, Zhang X, Xu X. Pharmacological inhibition of transient receptor potential vanilloid 4 (TRPV4) channel alleviates carbon tetrachloride-induced liver fibrosis in mice. <i>J. Nippon Med. Sch.<\/i>, <b>86<\/b>, 258\u2013262 (2019).","DOI":"10.1272\/jnms.JNMS.2019_86-407"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kim SY, Jeong J-M, Kim SJ, Seo W, Kim M-H, Choi W-M, Yoo W, Lee J-H, Shim Y-R, Yi H-S, Lee Y-S, Eun HS, Lee BS, Chun K, Kang S-J, Kim SC, Gao B, Kunos G, Kim HM, Jeong W-I. Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4-MD2 complex. <i>Nat. Commun.<\/i>, <b>8<\/b>, 2247 (2017).","DOI":"10.1038\/s41467-017-02325-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. <i>Nat. Med.<\/i>, <b>24<\/b>, 908\u2013922 (2018).","DOI":"10.1038\/s41591-018-0104-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Khamphaya T, Chukijrungroat N, Saengsirisuwan V, Mitchell-Richards KA, Robert ME, Mennone A, Ananthanarayanan M, Nathanson MH, Weerachayaphorn J. Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor. <i>Hepatology<\/i>, <b>67<\/b>, 560\u2013574 (2018).","DOI":"10.1002\/hep.29588"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Shimauchi T, Numaga-Tomita T, Ito T, Nishimura A, Matsukane R, Oda S, Hoka S, Ide T, Koitabashi N, Uchida K, Sumimoto H, Mori Y, Nishida M. TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. <i>JCI Insight<\/i>, <b>2<\/b>, e93358 (2017).","DOI":"10.1172\/jci.insight.93358"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, Ito T, Katsume A, Sudoh M. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. <i>Int. J. Exp. Pathol.<\/i>, <b>94<\/b>, 93\u2013103 (2013).","DOI":"10.1111\/iep.12008"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nishiyama K, Numaga-Tomita T, Fujimoto Y, Tanaka T, Toyama C, Nishimura A, Yamashita T, Matsunaga N, Koyanagi S, Azuma Y-T, Ibuki Y, Uchida K, Ohdo S, Nishida M. Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. <i>Br. J. Pharmacol.<\/i>, <b>176<\/b>, 3723\u20133738 (2019).","DOI":"10.1111\/bph.14777"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nishiyama K, Aono K, Fujimoto Y, Kuwamura M, Okada T, Tokumoto H, Izawa T, Okano R, Nakajima H, Takeuchi T, Azuma Y-T. Chronic kidney disease after 5\/6 nephrectomy disturbs the intestinal microbiota and alters intestinal motility. <i>J. Cell. Physiol.<\/i>, <b>234<\/b>, 6667\u20136678 (2019).","DOI":"10.1002\/jcp.27408"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nishida M, Tanaka T, Mangmool S, Nishiyama K, Nishimura A. Canonical transient receptor potential channels and vascular smooth muscle cell plasticity. <i>J. Lipid Atheroscler.<\/i>, <b>9<\/b>, 124\u2013139 (2020).","DOI":"10.12997\/jla.2020.9.1.124"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Staruschenko A, Spires D, Palygin O. Role of TRPC6 in progression of diabetic kidney disease. <i>Curr. Hypertens. Rep.<\/i>, <b>21<\/b>, 48 (2019).","DOI":"10.1007\/s11906-019-0960-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hofmann K, Fiedler S, Vierkotten S, Weber J, Klee S, Jia J, Zwickenpflug W, Flockerzi V, Storch U, Yildirim A\u00d6, Gudermann T, K\u00f6nigshoff M, Dietrich A. Classical transient receptor potential 6 (TRPC6) channels support myofibroblast differentiation and development of experimental pulmonary fibrosis. <i>Biochim. Biophys. Acta Mol. Basis Dis.<\/i>, <b>1863<\/b>, 560\u2013568 (2017).","DOI":"10.1016\/j.bbadis.2016.12.002"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Bailey K, Wang Z, Moak SP, Dai X, Fu Y, do Carmo JM, da Silva AA, Hall JE. TRPC6 deficiency causes obesity and metabolic dysfunction. <i>FASEB J.<\/i>, <b>33<\/b>, 753 (2019).","DOI":"10.1096\/fasebj.2019.33.1_supplement.753.1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nishiyama K, Tanaka T, Nishimura A, Nishida M. TRPC3-based protein signaling complex as a therapeutic target of myocardial atrophy. <i>Curr. Mol. Pharmacol.<\/i>, <b>14<\/b>, 123\u2013131 (2021).","DOI":"10.2174\/1874467213666200407090121"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Morgan ML, Sigala B, Soeda J, Cordero P, Nguyen V, Mckee C, Mouraliderane A, Vinciguerra M, Oben JA. Acetylcholine induces fibrogenic effects <i>via<\/i> M2\/M3 acetylcholine receptors in non-alcoholic steatohepatitis and in primary human hepatic stellate cells. <i>J. Gastroenterol. Hepatol.<\/i>, <b>31<\/b>, 475\u2013483 (2016).","DOI":"10.1111\/jgh.13085"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Seo K, Rainer PP, Shalkey Hahn V, Lee D-I, Jo S-H, Andersen A, Liu T, Xu X, Willette RN, Lepore JJ, Marino JP Jr, Birnbaumer L, Schnackenberg CG, Kass DA. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>111<\/b>, 1551\u20131556 (2014).","DOI":"10.1073\/pnas.1308963111"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/3\/44_b20-00903\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T09:17:26Z","timestamp":1671441446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/3\/44_b20-00903\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00903","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}